.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XX09_Daptomycin.Daptomycin

Information

Daptomycin is a cyclic lipopeptide antibiotic used for the treatment of infections caused by Gram-positive bacteria, including complicated skin and skin structure infections and Staphylococcus aureus bacteremia, including right-sided infective endocarditis. It is approved by the FDA and continues to be in clinical use.

Pharmacokinetics

Pharmacokinetic parameters for healthy adult volunteers after a single intravenous 4 mg/kg dose.

References

1. Wu, J, et al., & Wu, D (2024). Population pharmacokinetics of intravenous daptomycin in critically ill patients: implications for selection of dosage regimens. Frontiers in pharmacology 15 1378872–None. DOI:10.3389/fphar.2024.1378872 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38756382

2. Ishii, M, et al., & Yoshitsugu, H (2023). Pharmacokinetics of intravenous daptomycin in Japanese pediatric patients: Pharmacokinetic comparisons supporting dosing recommendations in Japanese pediatric patients. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 29(6) 592–598. DOI:10.1016/j.jiac.2023.02.012 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36868408

3. Liang, SH, et al., & Chang, SC (2009). Pharmacokinetics and safety of multiple intravenous doses of daptomycin in a Taiwanese adult population. Chemotherapy 55(2) 91–96. DOI:10.1159/000192392 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19145078

Revisions

• 06/2025 initial generated model